PubMed Health⌕ Search

Biomedical subjects

D Ramey

Publications and source records attributed to D Ramey.

11 recordsLinked to original sources
PubMed2001

Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.

We describe the progress towards developing a patient rated toxicity index that meets all of the patient-important attributes defined by the OMERACT Drug Safety Working Party. These attributes are frequency, severity, importance to patient, importance to the clinician, impact on economics, impact on activities, and integration of adverse effects with benefits. The Stanford Toxicity Index (STI) has been revised to collect all attributes with the exception of impact on activities. However, since the STI is a part of the Health Assessment Questionnaire (HAQ), impact on activities is collected by the HAQ. In particular, a new question asks patients to rate overall satisfaction, taking into consideration both benefits and adverse effects. The next step in the development of this tool is to ensure that the STI meets the OMERACT filter of truth, discrimination, and feasibility. Although truth and feasibility have been confirmed by comparisons within the ARAMIS database, discrimination needs to be assessed in clinical trials.

Adverse Drug Reaction Reporting Systems↗
PubMed2000

Distance learning: health education for ninth-grade students.

A telehealth programme for schools was established by staff at the East Carolina University schools of nursing, health education, social work, nutrition, education and medicine, in conjunction with the Eastern Area Health Education Center. A health education curriculum was developed for rural high schools using the North Carolina Information Highway for delivery. A Web page provided additional resources for teachers, teenagers and health professionals. Four telehealth sessions were conducted over three years: two with the pilot school and two with a second school on-line simultaneously. A total of 76 ninth-grade students completed the courses. Evaluation indicated successful outcomes in student learning. Respondents to a follow-up survey of members of the first telehealth class had positive comments about the experience. Utilization of the Web page increased steadily from 1997.

Education, Distance↗
PubMed1993

The relative toxicity of disease-modifying antirheumatic drugs.

OBJECTIVE: To compare the toxicities of commonly employed disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA). METHODS: Toxicity Index scores, computed from symptoms, laboratory abnormalities, and hospitalizations attributable to DMARD therapy, were assessed in 2,747 patients with RA receiving 3,053 courses of 6 DMARDs and 1,309 courses of prednisone over 7,278 patient-years. Results were adjusted for severity of illness and other covariates. RESULTS: Least toxic was hydroxychloroquine (mean +/- SEM score 1.38 +/- 0.15), followed by intramuscular gold (2.27 +/- 0.17) and the closely grouped D-penicillamine (3.38 +/- 0.36), methotrexate (3.82 +/- 0.35), and azathioprine (3.92 +/- 0.39). Auranofin (5.25 +/- 0.32) was most toxic, but this toxicity resulted from a high frequency of minor complications. Hospitalizations because of auranofin or hydroxychloroquine therapy were not noted. Prednisone (3.83 +/- 0.39) was of comparable toxicity, although it is likely that not all events of prednisone toxicity were captured. For reference, the toxicity of methotrexate and azathioprine was similar to that of the most toxic nonsteroidal antiinflammatory drugs (NSAIDs) (indomethacin 3.99, tolmetin sodium 3.96, and meclofenamate 3.86). Hydroxychloroquine showed less toxicity than the most commonly used prescription NSAIDs. CONCLUSION: There are substantial differences in toxicity among DMARDs and less important differences in toxicity between specific DMARDs and specific NSAIDs.

Anti-Inflammatory Agents↗
PubMed1980

Influence of genotype and diet on general performance and incidence of leg abnormalities of commercial broilers reared to roaster weight.

Two experiments were conducted to study the influence of genotype and diet on general performance and incidence of leg abnormalities of commercial broiler chickens reared to roaster weight. In Experiment 1 a total of 1960 male day-old chicks of seven different commercial genotypes were housed separately in 14 pens (25.64 m2) with 140 birds per pen and fed one dietary regimen. In experiment 2, 3000 male day-old chicks of two commercial genotypes were randomly assigned to 20 pens (13.54 m2) with 150 birds per pen, and two replicate pens were fed one of the five different dietary regimens designed to promote rapid, intermediate, or slow growth. Differences (P less than .05) were observed among the genotypes tested (Experiment 1) in the incidence of mortality, leg abnormalities, live weight, and feed conversion but not for mean monetary returns per bird housed. In Experiment 2, significant differences (P less than .01) were observed among the dietary regimens tested for live weight, feed conversion, and monetary returns per bird housed. As the protein content of starters, growers, and finishers decreased, body weight decreased but monetary returned improved. Feeding the birds beyond 63 days resulted in substantial reduction in monetary returns. A dietary regimen which included starter, grower, developer, and finisher with 18, 24, 22, and 14% protein, respectively, resulted in significantly better feed conversion and a significantly lower incidence of leg abnormalities. Genotype X diet interactions were considered of no practical importance.

Animal Feed↗